SG3 Management’s Sanofi SNY Stock Holding History

SG3 Management’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-75,000	Closed	-$3.62M	–	1266
2021 Q3	$3.62M	Buy	+75,000	New	+$3.81M	0.11%	186

Other funds holding SNY

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

SG3 Management's SNY Position: Q1 2022 in Review

SG3 Management sold out of Sanofi (SNY) in Q1 2022, closing a stake of 30,000 shares — an estimated $1.5M sold.

SG3 Management first reported a position in SNY in Q3 2021 and held it in 2 quarters. The position peaked at $1.5M in Q4 2021. 624 funds tracked by Wall St. Rank hold SNY as of Q1 2022.

SG3 Management reported no remaining Sanofi position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 30,000 Sanofi shares in Q1 2022, an estimated $1.5M.
SG3 Management first reported a position in Sanofi in Q3 2021 and held it in 2 quarters.
SG3 Management's Sanofi position peaked at $1.5M in Q4 2021.
624 funds tracked by Wall St. Rank held Sanofi as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.